Bosutinib/bosutinib efficacy price

Bosutinib/Bosutinib is one of five tyrosine kinase inhibitors currently approved for the treatment of chronic myeloid leukemia (CML). It forms a unique targeting combination through dual inhibition of Src and ABL kinases and targeting of other kinases, which also explains its different side effects from other drugs. Bosutinib was approved in 2013 for patients who have received prior therapy with one or more tyrosine kinases and for whom imatinib, nilotinib, and dasatinib are considered inappropriate candidates.

Although the initial first-line clinical trial of bosutinib and imatinib in patients with chronic phase CML failed to meet the primary endpoint and was therefore not licensed as first-line treatment, the subsequent BFORE study showed promising results, predicting that the drug's indications will be rapidly expanded. Compared with other approved tyrosine kinase inhibitors, bosutinib has unique side effects, with extremely low incidence of cardiovascular and thrombotic events, and relatively minor long-term safety issues, with most adverse events concentrated in the first few months of treatment.

The original drug of bosutinib has not yet been launched in the Chinese market, so the domestic price is not yet clear. Currently, in the international market, the Swiss, Turkish and European versions of the original drug are on sale. The Turkish version is 500mg*28 tablets and may be sold for more than 2,000 yuan; while the European and Swiss versions may be sold for 40,000 yuan, and price fluctuations will be affected by exchange rates. At the same time, there are also bosutinib generic drugs produced in some overseas countries, and their drug ingredients are basically the same as the original drug. For example, the 100mg*120 tablets produced in India may be sold for more than 1,000 yuan per box, which is cheaper than the original drug.

Reference materials:https://link.springer.com/chapter/10.1007/978-3-319-91439-8_4